PO035 ATHN 16: Safety of Coagulation Factor VIIA (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors with or without Prophylactic Treatment

Tammuella Chrisentery-Singleton, W Allan Alexander, Ahmad Al-Sabbagh, Miguel Escobar, Adam Giermasz, Janna Journeycake, Sonia Nasr, Doris Quon, Michael Recht, Daniel Bonzo, M Nikki Hirsh, Mark Reding, Michael Callaghan
15th Annual Congress of EAHAD Virtual
February 2-4, 2022
Chromogenic Method, Factor VIII, Antibody, Emicizumab

Can’t find what you’re looking for?
Please contact support@athn.org for assistance.